Security key
92790C104
Viridian Therapeutics, Inc.\DE - Common Stock (VRDN)
CUSIP: 92790C104
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 101,911,273
- Total 13F shares
- 93,206,736
- Share change
- -1,402,032
- Total reported value
- $2,011,267,436
- Put/Call ratio
- 238%
- Price per share
- $21.58
- Number of holders
- 168
- Value change
- -$24,960,784
- Number of buys
- 69
- Number of sells
- 83
Report period
Q3 2025
Institutions
168
Top holders
10
VRDN full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Viridian Therapeutics, Inc.\DE SEC filings
Viridian Therapeutics, Inc.\DE company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92790C104
Recent filing periods:
Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.5%
|
3,575,309
|
$48,373,931 | $0 | 31 Dec 2024 | |
| Commodore Capital LP |
13D/G
13F
|
Company |
3.9%
|
3,200,000
|
$69,056,000 | -$23,738,000 | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
12%
|
12,238,803
|
$171,098,466 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.4%
|
5,521,035
|
$77,184,070 | — | 30 Jun 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
5.3%
|
5,380,449
|
$75,218,677 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.4%
|
4,508,508
|
$63,028,941 | — | 30 Jun 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
4.3%
|
4,427,927
|
$61,902,419 | — | 30 Jun 2025 | |
| Venrock Adviser, LLC |
13F
|
Company |
3.8%
|
3,882,709
|
$54,280,272 | — | 30 Jun 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
3.4%
|
3,459,913
|
$48,369,584 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.8%
|
2,895,265
|
$40,477,000 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.8%
|
2,842,925
|
$39,744,092 | — | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.7%
|
2,741,576
|
$38,327,232 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
2,553,426
|
$35,696,895 | — | 30 Jun 2025 | |
| Novo Holdings A/S |
13F
|
Company |
2.3%
|
2,380,000
|
$33,272,400 | — | 30 Jun 2025 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
2.2%
|
2,257,010
|
$31,553,000 | — | 30 Jun 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.9%
|
1,944,020
|
$27,177,400 | — | 30 Jun 2025 | |
| Eversept Partners, LP |
13F
|
Company |
1.9%
|
1,902,539
|
$26,597,495 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.7%
|
1,744,406
|
$24,386,796 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
1,740,614
|
$24,337,019 | — | 30 Jun 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.3%
|
1,338,472
|
$18,711,839 | — | 30 Jun 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.3%
|
1,298,825
|
$18,157,574 | — | 30 Jun 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
1,265,754
|
$17,695,241 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.2%
|
1,207,871
|
$16,886,036 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.1%
|
1,108,586
|
$15,498,032 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.96%
|
982,576
|
$13,736,412 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.88%
|
899,825
|
$12,579,553 | — | 30 Jun 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.85%
|
862,273
|
$12,055,090 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.8%
|
815,485
|
$11,400,480 | — | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.72%
|
736,595
|
$10,297,598 | — | 30 Jun 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.69%
|
700,000
|
$9,786,000 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.64%
|
649,543
|
$9,080,611 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.59%
|
596,883
|
$8,344,424 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
574,021
|
$8,024,814 | — | 30 Jun 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.55%
|
564,790
|
$7,895,764 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.52%
|
533,643
|
$7,460,330 | — | 30 Jun 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.51%
|
515,623
|
$7,208,410 | — | 30 Jun 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.5%
|
509,959
|
$7,129,226 | — | 30 Jun 2025 | |
| Yiheng Capital Management, L.P. |
13F
|
Company |
0.49%
|
500,261
|
$6,993,649 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.48%
|
485,698
|
$6,792,520 | — | 30 Jun 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.48%
|
484,559
|
$6,774,135 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.46%
|
469,949
|
$6,569,886 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.44%
|
447,507
|
$6,256,148 | — | 30 Jun 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.42%
|
423,272
|
$5,917,343 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.41%
|
415,989
|
$5,815,525 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.38%
|
390,000
|
$5,452,200 | — | 30 Jun 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.38%
|
386,938
|
$5,409,393 | — | 30 Jun 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.37%
|
376,846
|
$5,268,307 | — | 30 Jun 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.35%
|
351,852
|
$4,918,891 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.34%
|
345,895
|
$4,835,000 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.33%
|
332,089
|
$4,642,604 | — | 30 Jun 2025 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) as of Q3 2025
As of 30 Sep 2025,
Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) was held by
168 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,206,736 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., Deep Track Capital, LP, Kynam Capital Management, LP, VANGUARD GROUP INC, VR ADVISER, LLC, Fairmount Funds Management LLC, Commodore Capital LP, TANG CAPITAL MANAGEMENT LLC, and Paradigm Biocapital Advisors LP.
This page lists
168
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
169
Q3 2025 holders
168
Holder diff
-1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.